NCT01430299View on ClinicalTrials.gov

Efficacy and Safety of Accell Evo3 Demineralized Bone Matrix (DBM) in Instrumented Posterolateral Lumbar Spine Fusion

NACompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

March 31, 2016

Study Completion Date

October 31, 2016

Conditions
StenosisSpondylosisDegenerative Changes
Interventions
DEVICE

Demineralized Bone Matrix

Accell Evo3 in posteriolateral fusion (prospective cohort)

DEVICE

rh-BMP2

rh-BMP2 in posterolateral fusion (retrospective cohort)

Trial Locations (1)

95816

University of CA-Davis, Dept. of Orthopaedics, Adult & Pediatric Spine Surgery, Sacramento

All Listed Sponsors
lead

SeaSpine, Inc.

INDUSTRY

NCT01430299 - Efficacy and Safety of Accell Evo3 Demineralized Bone Matrix (DBM) in Instrumented Posterolateral Lumbar Spine Fusion | Biotech Hunter | Biotech Hunter